TAVR Leaflet Thickening Side-Effect Should Not Change Practice – EuroPCR
This article was originally published in The Gray Sheet
New data presented at the EuroPCR conference in Paris suggest the valve leaflet thickening seen with St Jude Medical’s Portico transcatheter aortic valve is not a danger to patients.
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 19 January.
Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.
The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.